Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-08-16
DOI
10.1002/hon.2546
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft
- (2018) Ursina Gössi et al. HEMATOLOGICAL ONCOLOGY
- BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
- (2016) Stefanie Gilli et al. ANNALS OF HEMATOLOGY
- Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
- (2016) Bernard Maybury et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
- (2016) M Martino et al. BONE MARROW TRANSPLANTATION
- High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study
- (2015) Maurizio Musso et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation
- (2015) Nina Shah et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
- (2015) Mona Darwish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple myeloma
- (2015) Christoph Röllig et al. LANCET
- Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity
- (2015) Beatrice U. Mueller et al. LEUKEMIA & LYMPHOMA
- Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment
- (2015) Sandra Keller et al. LEUKEMIA RESEARCH
- Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study
- (2014) Massimo Martino et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers
- (2014) M. Mohty et al. HAEMATOLOGICA
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- European Perspective on Multiple Myeloma Treatment Strategies in 2014
- (2014) H. Ludwig et al. ONCOLOGIST
- A Phase 1 Study of Bendamustine and Melphalan Conditioning for Autologous Stem Cell Transplantation in Multiple Myeloma
- (2013) Tomer M. Mark et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- An old drug with a new future: bendamustine in multiple myeloma
- (2013) Massimo Gentile et al. EXPERT OPINION ON PHARMACOTHERAPY
- Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach
- (2012) Margarita Blanes et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
- (2012) S. Lentzsch et al. BLOOD
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
- (2012) L. Rosinol et al. BLOOD
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
- (2011) M. Cavo et al. BLOOD
- Current Trends in Autologous Stem-Cell Transplantation for Myeloma in the Era of Novel Therapies
- (2011) Philippe Moreau et al. JOURNAL OF CLINICAL ONCOLOGY
- Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
- (2010) J. J. Lahuerta et al. HAEMATOLOGICA
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)
- (2009) M. Roussel et al. BLOOD
- Autologous Hematopoietic Stem-Cell Transplantation for Multiple Myeloma
- (2009) Jean-Luc Harousseau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling
- (2008) G. Roue et al. CLINICAL CANCER RESEARCH
- Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents
- (2008) L. M. Leoni et al. CLINICAL CANCER RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started